INDV vs. BBIO, VRNA, TLX, TGTX, GRFS, LNTH, LEGN, AXSM, NUVL, and ADMA
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include BridgeBio Pharma (BBIO), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.
Indivior vs.
BridgeBio Pharma (NASDAQ:BBIO) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.
BridgeBio Pharma received 168 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 72.47% of users gave BridgeBio Pharma an outperform vote.
BridgeBio Pharma has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
Indivior has higher revenue and earnings than BridgeBio Pharma. Indivior is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, BridgeBio Pharma had 9 more articles in the media than Indivior. MarketBeat recorded 13 mentions for BridgeBio Pharma and 4 mentions for Indivior. Indivior's average media sentiment score of 1.72 beat BridgeBio Pharma's score of 0.80 indicating that Indivior is being referred to more favorably in the news media.
Indivior has a net margin of -3.96% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Indivior's return on equity.
BridgeBio Pharma currently has a consensus target price of $57.09, indicating a potential upside of 73.85%. Indivior has a consensus target price of $15.00, indicating a potential upside of 32.86%. Given BridgeBio Pharma's higher possible upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Indivior.
Summary
BridgeBio Pharma beats Indivior on 10 of the 19 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
This page (NASDAQ:INDV) was last updated on 5/22/2025 by MarketBeat.com Staff
